首页> 美国卫生研究院文献>Stem Cells Translational Medicine >Cartilage Repair Using Human Embryonic Stem Cell-Derived Chondroprogenitors
【2h】

Cartilage Repair Using Human Embryonic Stem Cell-Derived Chondroprogenitors

机译:使用人类胚胎干细胞衍生的软骨生成器修复软骨

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In initial work, we developed a 14-day culture protocol under potential GMP, chemically defined conditions to generate chondroprogenitors from human embryonic stem cells (hESCs). The present study was undertaken to investigate the cartilage repair capacity of these cells. The chondrogenic protocol was optimized and validated with gene expression profiling. The protocol was also applied successfully to two lines of induced pluripotent stem cells (iPSCs). Chondrogenic cells derived from hESCs were encapsulated in fibrin gel and implanted in osteochondral defects in the patella groove of nude rats, and cartilage repair was evaluated by histomorphology and immunocytochemistry. Genes associated with chondrogenesis were upregulated during the protocol, and pluripotency-related genes were downregulated. Aggregation of chondrogenic cells was accompanied by high expression of SOX9 and strong staining with Safranin O. Culture with PluriSln1 was lethal for hESCs but was tolerated by hESC chondrogenic cells, and no OCT4-positive cells were detected in hESC chondrogenic cells. iPSCs were also shown to generate chondroprogenitors in this protocol. Repaired tissue in the defect area implanted with hESC-derived chondrogenic cells was stained for collagen II with little collagen I, but negligible collagen II was observed in the fibrin-only controls. Viable human cells were detected in the repair tissue at 12 weeks. The results show that chondrogenic cells derived from hESCs, using a chemically defined culture system, when implanted in focal defects were able to promote cartilage repair. This is a first step in evaluating these cells for clinical application for the treatment of cartilage lesions.
机译:在最初的工作中,我们在潜在的GMP(化学定义的条件)下开发了14天的培养方案,以从人类胚胎干细胞(hESCs)生成软骨生成剂。进行本研究以研究这些细胞的软骨修复能力。软骨生成协议进行了优化,并通过基因表达谱进行了验证。该协议也成功地应用于诱导多能干细胞(iPSCs)的两行。将源自hESC的软骨细胞封装在纤维蛋白凝胶中,并植入裸鼠the骨沟的骨软骨缺损中,并通过组织形态学和免疫细胞化学评估软骨修复。在协议期间,与软骨形成相关的基因被上调,而与多能性相关的基因被下调。软骨细胞的聚集伴随着SOX9的高表达和番红O的强烈染色。用PluriSln1培养的hESC具有致死性,但hESC软骨细胞可以耐受,并且在hESC软骨细胞中未检测到OCT4阳性细胞。在该方案中,iPSC还显示出可产生软骨生成剂。移植有hESC衍生软骨细胞的缺损区域中的修复组织被染色,胶原蛋白II几乎不含胶原蛋白I,但在仅血纤蛋白的对照中观察到的胶原蛋白II可以忽略不计。在第12周在修复组织中检测到活的人细胞。结果表明,使用化学成分明确的培养系统,从hESCs衍生的软骨细胞在植入局灶性缺损时能够促进软骨修复。这是评估这些细胞在临床上用于治疗软骨损伤的第一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号